31 results about "Large cell" patented technology

Aiming at the problem that a conventional mask cannot absorb large cells through natural permeation, the invention provides the preparation method of the nano-microsphere cell active factor mask, and the nano-microsphere cell active factor mask is prepared through the processes of preparing an emulsion system, solidifying small liquid drops, alkalizing materials such as polymer collagen / chitosan microspheres, stirring to prepare a nano-microsphere cell active stock solution and the like. According to the prepared polymer collagen / chitosan porous microspheres, cell active factors are diffused into the pore diameters of the microspheres, the permeability of active factor cells is improved through a microsphere carrier, and proliferation and growth of skin epidermal cells are greatly promoted.

The invention discloses a multi-scale feature fusion cervical abnormal cell detection method, and relates to the technical field of medical image processing and deep learning. Firstly, a cervical lesion cell detection method based on multi-scale feature fusion is used, efficient capture of multi-scale features from local details to an overall structure in a cervical lesion cell image is achieved by providing a CSPM, the CSPM can dynamically extract the features among different scales, context information is fully utilized, and the detection accuracy of the cervical lesion cells is improved. The method comprises the following steps of: firstly, designing a multi-scale fusion attention module, so that the defect of single-scale characteristics in expression capability is overcome, the problems of large cell size change and complex background are effectively solved, secondly, the designed multi-scale fusion attention module further enhances the characteristic fusion capability, and the MSFA can adaptively adjust the weights of different-scale characteristics according to the importance of the cell characteristics, so that the fusion accuracy is improved. And local and global information is fully fused, so that the capability of sensing and identifying the abnormal cervical cells by the network is improved.

The invention discloses application of a mast cell polarization typing detection kit, and belongs to the field of biological medicine. The kit comprises a mast cell characteristic enzyme TPSB2 detection reagent, and one or more of a mast cell MC1 type polarization detection reagent and a mast cell MC2 type polarization detection reagent, the MC1 type polarization is CCL27, and the expression of TNF-alpha is up-regulated; and the MC2 type polarization comprises expression up-regulation of CCL3, IL-16 and VEGFA (vascular endothelial growth factor A). Mstoma cells have dual effects in a tumor microenvironment, can promote tumor progression, and also can enhance anti-tumor immune response. The mastocyte polarization typing is identified through the expression level of the biomarker, so that the mastocyte polarization typing can be rapidly and accurately evaluated, identification indexes and tools are provided for further discussing the functions of mastocytes in different polarization states, cancer diagnosis can be assisted, the onset risk of cancer can be reduced, and the method is suitable for popularization and application. And an immunotherapy target is provided for clinical treatment of cancers.

The invention relates to the technical field of neutrophile granulocyte separation, in particular to a mouse neutrophile granulocyte separation method which comprises the following steps: (1) anesthetizing and disinfecting a mouse; (2) tissue sampling; (3) tissue digestion; (4) preparing a cell suspension; (5) purifying cells; (6) cell culture; according to the method disclosed by the invention, isoflurane is adopted in the anesthesia disinfection step, so that central nervous activity of mice can be rapidly inhibited, tissue damage caused by stress reaction is avoided, and chemical stimulation can be reduced while body surface microorganisms are cleared through combination of ethanol disinfection and sterile normal saline flushing, and aortic tissues with intact activity are provided for subsequent material taking. In the compound enzyme digestive juice, collagenase I can specifically degrade aortic wall collagenous fibers, trypsin dissociates adhesion connection between cells, neutral protease assists in decomposing elastic fibers, and DNA enzyme I is supplemented to inhibit cell aggregation, so that the contradiction between incomplete digestion and large cell damage of the traditional enzyme juice is effectively solved.

The present invention discloses a computer device and computer-readable storage medium for identifying or assisting in the identification of large cell transformation of mycosis fungoides. The present invention provides a computer device comprising a memory, a processor, and a computer program stored in the memory, wherein the processor performs the following steps: S1) data reception: receiving the percentage of FOXM1-positive cells in skin lesions of a subject with mycosis fungoides (MF); S2) data output: outputting result information from the computer based on the percentage of FOXM1-positive cells, wherein the result information indicates whether the subject with mycosis fungoides has, or is a candidate for, large cell transformation of mycosis fungoides. Experiments in the present invention demonstrate that immunohistochemical staining for FOXM1 can more accurately locate large cells and quantify the proportion of large cells compared to traditional pathological techniques, thereby reducing subjective bias. Therefore, it is proposed that immunohistochemical staining for FOXM1 can be used as an auxiliary technique for diagnosing large cell transformation of mycosis fungoides.

The invention discloses double-mesoporous silica nanoparticles for modifying ionizable amino and a preparation method and application of the double-mesoporous silica nanoparticles. The core technical process of the double-mesoporous silica nanoparticles comprises the following steps: firstly, synthesizing mesoporous silica through a double-template method of a block copolymer and a surfactant; then grafting ionizable amino to the surface of the mesoporous silica through a silane coupling agent; and finally, RNA is loaded on the modified mesoporous silica by electrostatic adsorption, and efficient tumor treatment is finally realized. The invention also discloses an application of the silicon dioxide nanoparticles in RNA delivery. The silicon dioxide nanoparticles prepared according to the method disclosed by the invention have high RNA loading efficiency and cell uptake efficiency. The double-mesoporous silica nanoparticles modified with ionizable amino groups have the advantages of large drug loading capacity, high cell uptake rate, high biocompatibility, simplicity in synthesis, mild reaction conditions, convenience in cutting and the like, and have a good application prospect.

The invention discloses a stem cell-based microvesicle as well as a preparation method and application thereof, belongs to the technical field of biological tissue engineering, and particularly relates to a preparation method of the stem cell-based microvesicle, which comprises the following steps: culturing stem cells until the cell fusion degree is 80-90%, performing hypoxia treatment, and cleaning for 2-3 times; standing and culturing the cleaned stem cells, then adding a calcium ion carrier, and carrying out ultrasonic treatment; the serum-free basic culture medium containing the calcium ion carrier is immediately absorbed and removed, the cells are cleaned through PBS, culture is conducted for 24 h, and cell supernatant is collected and merged respectively; performing first centrifugation to remove cell debris; performing second centrifugation to remove dead cells and large cell debris; carrying out third centrifugation to remove organelles; fourth centrifugation is carried out, large vesicles are removed, and a final supernatant is obtained; and filtering and centrifuging to obtain a microvesicle precipitate. The preparation method of the microvesicles aims at systematically improving the yield and biological activity of the stem cell microvesicles through low-oxygen pre-stimulation, ultrasonic-calcium ion carrier synergistic induction and differential centrifugation.

According to the invention, a novel immune checkpoint molecule SIDT1 is found. The SIDT1 is a powerful T cell inhibition factor mainly expressed on CD8 < + > T cells. A series of SIDT1 inhibitors are identified in the invention. The SIDT1 inhibitor can enhance the anti-tumor CD8T cell reaction and limit tumor progression, so that a new thought is provided for treatment and prevention of related tumor patients with PD-1 treatment resistance.

The invention relates to methods for extracting, purifying and concentrating mesenchymal stromal cell exosomes enriched with micro-RNA, proteins and lipids, and can be used in cosmetology and pharmacology for rehabilitation and regeneration. The technical result of the invention is a more efficient process for producing exosomes. This technical result is achieved in that the present method for extracting, purifying and concentrating exosomes from mesenchymal stromal cells includes cultivating cells, collecting the conditioned culture medium, depleting high-molecular-weight proteins, extracting, purifying and concentrating exosomes, and freezing and lyophilizing the exosome concentrate; in order to enrich the culture medium with exosomes, multipotent mesenchymal stem cells (MSCs) are grown in a medium having a lowered glucose concentration and containing platelet lysate and 5 mM of L-alanyl-L-glutamine, wherein, in the case of static cell cultivation, the growth medium is placed in a culture vessel and once a level of not less than 80% monolayer confluence is reached, the culture medium is harvested and replaced once every 24 hours, and in the case of flow-through cell cultivation, cells are placed on cell carriers in a bioreactor and 72-96 hours after the start of cultivation, the culture medium is harvested and replaced once every 24 hours, the exosome-enriched culture medium is subjected to concentration, which includes successive stages of centrifugation, tangential flow filtration and isopycnic centrifugation: in the first stage, the culture medium is centrifuged for 10 mins at 2000 g to remove large cell particles and other inclusions; in the tangential flow filtration stage, the supernatant is concentrated using hollow fibre filters having a molecular weight cutoff of 500 kDa, after which the concentrate is subjected to fivefold diafiltration with an equal volume of DPBS phosphate buffer solution using the same hollow fibre cartridge; and in the isopycnic centrifugation stage, the concentrated supernatant is mixed with a saccharose solution and deuterium oxide and subjected to isopycnic centrifugation at 100000 g and 4˚С for 75 mins, after which the concentrate is subjected to further fivefold diafiltration with a buffer solution, then the concentrate is filtered through filters with a pore diameter of 0.22 µm and 0.1 µm, the exosome concentrate is subjected to initial freezing to -75˚C in a freezing chamber, and drying is carried out in a lyophilization chamber, wherein in a first drying stage, the concentrate is cooled to -40˚С and subsequently held for 100 mins at an absolute pressure in the chamber of not more than 10 Pa, then cooled to -30˚С and subsequently held for 610 mins at an absolute pressure in the chamber of not more than 10 Pa, then cooled to -10˚С and subsequently held for 315 mins at an absolute pressure in the chamber of not more than 10 Pa, after which it is cooled to 0˚С and subsequently held for 130 mins at an absolute pressure in the chamber of not more than 10 Pa, then heated to +10˚С and subsequently held for 130 mins at an absolute pressure in the chamber of not more than 10 Pa; in a second drying stage, drying is carried out at +22˚С for not less than 130 minutes at an absolute pressure in the chamber of not more than 10 Pa.

Adoptive cell therapy, and related methods, compositions, uses, and articles of manufacture, are provided that include administration of a dose of cells for treating a subject having a particular B cell malignancy. The cells generally express a recombinant receptor, such as a chimeric antigen receptor (CAR). In some embodiments, the disease or condition is large cell type B cell lymphoma (LBCL) that is refractory or relapsed to frontline chemoimmunotherapy.

The present invention provides a method for preparing a nutritional composition of xenogenic EVs from tissues / organs, comprising steps of collecting tissue / organ sample from fetal or adult mammal (101), keeping the collected sample in buffered saline in cold (102), mincing it into small pieces (103) and then mixing them with collagenase and deoxyribonuclease (104) followed by incubation and agitation (105), filtrating the incubated sample pieces for obtaining a filtrated liquid suspension containing extracellular fluid having EVs (106), differentially centrifuging the liquid suspension to remove remaining cells and tissue debris and obtain a supernatant (107), filtering the supernatant for collecting a crude fraction of large EVs (108) and centrifuging the supernatant for enriching it into a fraction of smaller EVs (109), characterized in that the separated EVs are fetal EV cargo or sinusoidal EVs directly isolated from the collected samples, wherein these EVs have regenerative potency, and the cells remain intact during EV isolation.

This disclosure provides medicaments and methods for treating envenomation using small molecule inhibitors of secretory phospholipase A2 (sPLA2). The sPLA2 inhibitor AZD2716 and related compounds can be used as monotherapy. Alternatively, the sPLA2 inhibitor varespladib and / or methyl varespladib can be used in combination with a statin. When a subject has been envenomed (for example, by a snake bite or bee sting), the medicaments can be administered to prevent lethal effects or tissues damage cause by the venom: for example, acute kidney injury, mast cell degranulation, or cerebral edema. The medicaments may be contained in an automatic injection device or an injection pen to deliver an effective dose as soon as possible following envenomation.

The present application relates to a molecular marker combination and detection reagent for identifying human blood mast cell precursor cells and application, and belongs to the technical field of cell detection. The molecular marker combination can realize efficient identification of human blood mast cell precursor cells, provide a new means for diagnosis of allergic diseases, and provide a new target for intervention of allergic diseases. The present application provides a molecular marker combination for identifying human blood mast cell precursor cells, wherein the molecular marker comprises a human cell surface molecule and a human intracellular molecule, the human cell surface molecule comprises CD34 and Fc epsilon R1 alpha, and the human intracellular molecule comprises CPA3, TPSAB1 and GATA2.

The invention discloses application of MRGPRX2 in diagnosis and treatment of esophageal cancer, and belongs to the field of biological medicine. The application comprises a reagent capable of detecting the MRPGRX2 or the expression quantity of the MRPGRX2, an application of the reagent in preparation of a kit for auxiliary diagnosis of esophageal cancer, or an application of the reagent in screening of potential drugs for treating esophageal cancer. The invention relates to a reagent capable of detecting MRPGRX2 or the expression quantity of MRPGRX2, and application of the reagent in preparation of a reagent for detecting the polarization state of mast cells. The invention relates to an application of a component for inhibiting or blocking MRPGRX2 expression in preparation of a medicine for treating esophageal cancer. The component for inhibiting or blocking the expression of MRPGRX2 is used for preparing a medicine for blocking the promotion effect of mast cells on invasion and migration of esophageal cancer cells. The expression level of MRGPRX2 in mast cells is changed through molecular biology means such as construction of MRGPRX2 specific siRNAs, and it is revealed that M2 polarization of the mast cells can be remarkably inhibited by interfering MRGPRX2 expression, and then tumor cell biological phenotypes such as invasion and migration of esophageal cancer cells are inhibited. Therefore, the MRGPRX2 can be used as a new tumor immunotherapy target to be applied to preparation and screening of drugs for detecting esophageal cancer prognostic markers or inhibiting esophageal cancer invasion and migration, and a new method is provided for prognostic evaluation or treatment of esophageal cancer.

The invention discloses a near-infrared light response fatty acid copper nano-drug as well as a preparation method and application thereof. According to the near-infrared light response fatty acid copper nano-drug, copper nanoparticles serve as a core, the outer layer of the copper nanoparticles is wrapped with a phase-change material organic shell layer, meanwhile, a copper ion carrier is loaded in the organic shell layer, and mitochondrial targeting lipid is modified on the shell layer. The nano-drug constructed by the invention can target tumor cells with high expression of CD36 and increase the dosage in the cells, has good mitochondrial targeting and space-time controllable release characteristics, shows a good photo-thermal treatment effect, can kill the tumor cells more accurately and controllably, and establishes a new strategy for cancer treatment.

The present application belongs to the technical field of nucleic acid delivery and gene editing, and particularly relates to a method for knocking out a target gene of a cell in vitro by using an LNP delivery system. In view of the technical problems of unstable editing efficiency, large difference in editing efficiency between different individuals, low transfection efficiency, large cell damage, unstable knockout effect and the like when a T cell is transfected by using an existing LNP for gene editing, the present application provides a method for efficiently knocking out a target gene of a T cell in the form of LNP by optimizing the LNP and LNP transfection operation parameters in a systematic manner. The method can effectively solve the above technical bottlenecks, realize efficient and stable knockout of a target gene of a T cell, and provide reliable technical support for T cell function research and immunotherapy application.

According to the present invention, a pharmaceutical composition for preventing and treating lung adenocarcinoma, comprising K-ras-specific activated T cells, is used as an antigen composition designed such that a K-ras mutant (G12D, G12V, and G13D) recombinant overlapping peptide is sequentially divided into a total of 12 epitopes (n=1 to 12, and the last epitope (n=12) consists of 23 amino acids) in units of 30 amino acids in the amino acid sequence of K-ras, and 15 amino acid sequences overlap between the epitopes. Thus, the pharmaceutical composition is more effective in recognizing and killing lung adenocarcinoma in which K-ras, K-ras mutant G12V, K-ras mutant G12D, or K-ras mutant G13D is detected. Therefore, according to the present invention, the pharmaceutical composition for preventing and treating lung adenocarcinoma, comprising K-ras-specific activated T cells, can be used to effectively prevent and treat lung adenocarcinoma, particularly lung large cell adenocarcinoma, in which K-ras as well as K-ras mutants are detected.

Disclosed are a delivery system based on sensitized mast cells, a preparation method therefor, and an application thereof, as well as a pharmaceutical composition and a drug administration device involving the delivery system of sensitized mast cells. The delivery system utilizes the specific recognition of tumor antigens by sensitized mast cells to targetedly deliver drugs to tumor cells, while protecting the drugs from the clearance of the circulating immune system. Sensitized mast cells rapidly degranulate under the activation of tumor antigens to release drugs, thereby enhancing infection, exerting an oncolytic effect, lysing tumor cells and releasing antigens, and activating an anti-tumor immune response. The delivery system can be used as a promising platform technology for personalized therapy.

The present invention discloses an intelligent responsive copper-death nanomedicine, its preparation and anti-tumor application. The intelligent responsive copper-death nanomedicine is obtained by loading a copper ion carrier in an intelligent responsive nanocarrier. The intelligent responsive nanocarrier uses copper nanoparticles as the core, and its outer layer is wrapped with a shell of organic mesoporous silica containing X-ray responsive double bonds, and the shell is modified with an acid-responsive polymer. The intelligent responsive nanocarrier has multiple responsive stimulation effects, which can change the charge carried by the drug-carrying system and increase the amount of drug administered into the cell; and has a drug delivery system with good targeting and spatiotemporal controlled release, which can reduce the toxic and side effects of drug molecules on other normal tissues and achieve precise treatment of tumors. The intelligent responsive copper-death nanomedicine can combine the metabolic therapy controlled by copper death with immunotherapy, which will effectively improve tumor resistance, reduce the side effects of radiotherapy on the whole body, and improve the survival rate of patients.

The invention discloses a computer device and a computer readable storage medium for identifying or assisting in identifying transformation of mushroom-like granulomegaly cells. The invention provides a computer device, which comprises a memory, a processor and a computer program stored on the memory, and the processor executes the following steps: S1) data receiving: receiving the percentage of FOXM1 positive cells in skin lesion tissues of a mushroom granuloma (MF) subject; and S2) data output: outputting result information from a computer based on the percentage of the FOXM1 positive cells, wherein the result information indicates whether the mushroom-like granuloma subject is or is candidate to be the transformation of the mushroom-like granuloma cells. Experiments prove that compared with a traditional pathological technology, immunohistochemical staining of FOXM1 can more accurately position large cells and quantify the proportion of the large cells, and subjective bias can be reduced. Therefore, the immunohistochemical staining of the FOXM1 can be used as one of auxiliary technologies for diagnosing the transformation of the mushroom-like granulomegaly cells.

The invention belongs to the technical field of exosome application, and discloses application of a sarcodon aspratus exosome in preparation of a medicine for treating interstitial cystitis. The prepared sarcodon aspratus exosome is perfused into the bladder of a rat with interstitial cystitis, and it is found that the sarcodon aspratus exosome can significantly improve urination disorder of the model rat and relieve symptoms of interstitial cystitis. In addition, the invention also finds that (1) the sarcodon aspratus exosome can obviously reduce the expression of IL-1beta, IL-6, MCP-1, CXCL-1, ICAM-1 and BAX in the bladder tissue; (2) the sarcodon aspratus exosome can significantly reduce the activation number of mast cells and inhibit degranulation of the mast cells; and (3) the sarcodon aspratus exosome can significantly improve epithelial cell apoptosis. The research shows that the sarcodon aspratus exosome can be used for treating interstitial cystitis. The research provides a new idea for the treatment of interstitial cystitis.

A method for obtaining a genetically engineered leukocyte composition is provided. The method includes: (a) enriching a population of large cells from a biological sample obtained from a subject, wherein the biological sample comprises leukocytes without performing density gradient centrifugation; (b) contacting the population of large cells with an activating agent; and (c) transducing the population of large cells with a viral vector comprising a polynucleotide. The enriching comprises an array-based separation comprising a microfluidic device configured for deterministic lateral displacement comprising an array of obstacles, and the obstacles are elongated so that their length perpendicular to bulk fluid flow (P1) is longer than their width parallel to bulk fluid flow (P2) by at least 10%.

The present invention relates to the field of biomedicine technology, and in particular to a culture medium, culture method and application for endothelial progenitor cells. The present invention improves the culture medium for endothelial progenitor cells, and the endothelial progenitor cells prepared therefrom have higher proliferation activity and better angiogenesis ability, and their ability to promote the secretion of active factors is the strongest. Factors such as IL-10 and TGF-β secreted by EPCs have the potential to inhibit mast cell degranulation, reduce the release of histamine and inflammatory mediators, and thus relieve wheals and itching. In addition, EPCs promote endothelial cell proliferation by secreting factors such as VEGF and Ang-1, repair damaged vascular endothelium, and reduce vascular leakage and edema. In urticarial vasculitis, EPCs can inhibit excessive proliferation of the vascular endothelium and relieve chronic inflammation. The culture medium of the present invention can be used for endothelial progenitor cell culture, which is helpful for screening potential drugs for treating urticaria and has great application value.

The application discloses a high-purity NKT cell preparation and a preparation method and a cryopreservation regulation method, and belongs to the fields of cell biology technology and immunotherapy. The method systematically solves multiple challenges of low purity, insufficient amplification efficiency, poor cell viability, high cost and difficulty in large-scale production of NKT cells in the prior art through a unique secondary cryopreservation process, innovative application of platelet lysate and specific induction of alpha-galactosylceramide (alpha-GalCer). The prepared NKT cell preparation has the advantages of high purity, large amplification fold, strong cell function activity and good safety, and provides a high-quality and standardized cell source for clinical applications such as tumor immunotherapy, and has great industrialization prospects.

Devices and methods for preparing adipose tissue for transplantation from leaflet fat extracted, for example by fat aspiration, the fat consisting of a fluid component comprising an oil component, a blood component and / or a disinfecting solution, and a solid component comprising an oil component, a blood component and / or a sterilizing solution, the invention relates to a device for washing and separating solid components comprising cell debris, cells and one or more large cell masses of different sizes, in which the device comprises at least one washing and separating container (1) having a washing chamber (101), said container (1) having an inlet (102) and an outlet (103), the invention relates to a washing chamber (101) for letting liposuction material into the washing chamber (101) through an inlet (102) and for letting at least a portion of said material out of said chamber (101) through said outlet (103), said washing chamber (101) comprising stirring means for forming an emulsion of a fluid component.

A drug delivery system based on sensitized mast cells, its preparation method, and its application are disclosed, along with a pharmaceutical composition and delivery device involving the sensitized mast cell delivery system. This delivery system utilizes the specific recognition of tumor antigens by sensitized mast cells to target and deliver drugs to tumor cells while protecting them from clearance by the circulating immune system. Upon activation by tumor antigens, sensitized mast cells rapidly degranulate to release the drug, thereby enhancing infection response, exerting an oncolytic effect, lysing tumor cells and releasing antigens, and activating an anti-tumor immune response. This delivery system can serve as a promising platform technology for personalized therapy.

The present invention relates to the use of compounds such as compounds of formula (I) or pharmaceutically acceptable salts, solvates and / or prodrugs thereof, for example the use of the compounds in pharmaceutical compositions and in the treatment of diseases, disorders or conditions, wherein the diseases, disorders or conditions include treatable by inhibition of SWAP-70 and / or treatable by inhibition of neutrophil reactive oxygen species (ROS) production, neutrophil extracellular trap formation (NETosis), B lymphocyte plasma mother cell development, B lymphocyte IgE production, mast cell degranulation, eosinophilic granulocyte ROS production, mast cell cytokine release, B lymphocyte IgE production, B lymphocyte IgE production, B lymphocyte IgE production, B lymphocyte IgE production, B lymphocyte IgE production, B lymphocyte IgE production, B lymphocyte IgE production, B lymphocyte IgE production, B lymphocyte IgE production and B lymphocyte IgE production. The composition can be used for treating diseases, symptoms or conditions, such as lung inflammation induced by viruses such as SARS-CoV-2 and the like, which can be treated by virtue of cytokine release of B lymphocytes, cytokine release of endothelial cells, interaction of endothelial cells and immune cells and / or migration of macrophages / monocytes. # imgabs0 #

The invention discloses a cell suction device for immune cell detection for nerve infection, relates to the technical field of cell suction devices, and provides the following scheme that the cell suction device comprises a suction device, a cell filtering piece is arranged at the front end of the suction device, and an expansion and contraction structure is fixedly connected into an inner cavity of the cell filtering piece. According to the cell suction device provided by the invention, the end of the cell suction device is arranged to be of an expandable and contractible structure, the suction nozzle can be quickly and easily mounted and replaced, meanwhile, the connection firmness between the cell suction device and the suction nozzle is improved, the jacket fitting a hand holding curve is arranged on the periphery of the cell suction device, anti-skid lines are arranged on the periphery of the jacket, and the jacket can be clamped with the wrist, so that the cell suction device is convenient to use. The suction device is prevented from being separated from the hand, and stability is improved. A replaceable filter screen structure is arranged in the suction end, a filter screen is connected through magnetic suction, the filter screen can be of a screen structure or a membrane structure, and the effects of screening out overlarge cells, bonding double cells and even dead cells are achieved.

The invention discloses a synthesis method and application of tumor microenvironment GSH / pH dual response type copper-based self-assembly nanoparticles, and belongs to the technical field of nano material preparation. The preparation method comprises the following steps: self-assembling copper ions, 3, 3 '-dithio-bis-propionyl hydrazide and a copper chaperonin inhibitor DCAC50, and carrying out surface modification by using F-127, so as to obtain the copper-based self-assembled nanoparticles. The material can respond to GSH / acidic pH of TME, released Cu < 2 + > is reduced into Cu under the action of high-concentration GSH, a large amount of active oxygen is generated through a Fenton-like reaction while copper death is triggered, and oxidative stress in cells is amplified; the released DCAC50 inhibitor can block Cu efflux mediated by copper chaperonin Atox1, and copper ion outflow is inhibited. Through double regulation and control of copper metabolism kinetics, tumor cell copper death is synergistically induced, oxidative stress is enhanced, and the efficient anti-tumor effect is achieved.